Kilitch Drugs (India)NSE:KILITCH -2.89%84 EBITDA Margin % is 25.26% as of Mar. 2026, which is 79% above its 10-year median of 14.14. GuruFocus rates NSE:KILITCH with a GF Score™ of 84/100 and a GF Value™ of ₹225.33 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Kilitch Drugs (India) ranks better than 68.59% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kilitch Drugs (India) EBITDA Margin % Related Terms
Kilitch Drugs (India) EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kilitch Drugs (India)'s EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kilitch Drugs (India) EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kilitch Drugs (India)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kilitch Drugs (India) (NSE:KILITCH) has a EBITDA Margin % of 25.26% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kilitch Drugs (India) and its competitors. This is 79% above median its historical median of 14.14. Over the past decade, Kilitch Drugs (India)'s EBITDA Margin % has ranged from 1.62 to 21.49. According to the industry distribution chart, Kilitch Drugs (India) ranks #300 out of 955 companies in the Drug Manufacturers industry, placing it in the top 31.4%.
Is Kilitch Drugs (India)'s EBITDA Margin % too high?
Kilitch Drugs (India)'s current EBITDA Margin % of 25.26% is 79% above median its 10-year median of 14.14. Over the past 10 years, this metric has ranged from a low of 1.62 to a high of 21.49. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Kilitch Drugs (India)'s value of 25.26% is 103.1% above this industry median. Based on the distribution chart, Kilitch Drugs (India) ranks #300 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kilitch Drugs (India) has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kilitch Drugs (India) ranks #300 out of 955 companies for EBITDA Margin %. This puts Kilitch Drugs (India) in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Kilitch Drugs (India)'s value of 25.26% is 103.1% above this benchmark. Historically, Kilitch Drugs (India)'s own EBITDA Margin % has ranged from 1.62 to 21.49 over the past decade. While the company's 10-year median is 14.14 vs. the industry median of 12.44, Kilitch Drugs (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kilitch Drugs (India)'s current EBITDA Margin % of 25.26% is 103.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kilitch Drugs (India) and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kilitch Drugs (India)'s current EBITDA Margin % is 25.26%, which is 79% above median its own 10-year median of 14.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹225.33, compared to a current price of ₹185.31 — trading 17.8% below its estimated fair value. The current EBITDA Margin % is 25.26%, which is 79% above median its 10-year median of 14.14 and 103.1% above the Drug Manufacturers industry median of 12.44. Kilitch Drugs (India)'s overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current EBITDA Margin % is 25.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?
Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued.
The current stock price of ₹185.31 is trading 17.8% below its estimated GF Value™ of ₹225.33.
GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.
Key valuation signals for NSE:KILITCH:
EBITDA Margin %: 25.26% (79% above median its 10-year median of 14.14)
GF Value™: ₹225.33 vs. price of ₹185.31 (17.8% below fair value)
Industry Position: 103.1% above the Drug Manufacturers median (#300 of 955)
No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score
Get the complete analysis for NSE:KILITCH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KILITCH has been successfully added to your 
